chrisvoncsefalvay/vaers-outcomes huggingface dataset:
In May of 2022 I was diagnosed with tendonitis and carpal tunnel.  It got progressively worse.  In July 2022 I had numbness in both hands.  I had a nerve study done.  I saw a neurologist and I was diagnosed with permanent nerve loss in three digits.  I still thought it was due to carpal tunnel.  My sports doctor had set up consult with the hand surgeon and neurologist and referred to a rheumatologist.  I saw this doctor in mid-September.  I also have had joint pain.  Unable to cut with a knife, hold a fork or open a bottle.  I began occupational therapy.  As of today, I am feeling better because I have been taking steroid medication as prescribed.
Pt had inconsolable crying at night for over 2 hours within 24 hours of receiving the injection. This continued for 3 days after the injection.
2 weeks following 2nd dose: shingles Then enlarged liver Then cervical polyp Following polyp removal two different UTIs Then bacterial vaginosis Waiting for further liver eval, in meantime experiencing chest inflammation, lip quivering, and blood in stool.
Agitated; low blood pressure; anxious and jittery; fatigued, didn't want to get out of bed; This spontaneous case was reported by a consumer and describes the occurrence of AGITATION (Agitated), HYPOTENSION (low blood pressure), ANXIETY (anxious and jittery) and FATIGUE (fatigued, didn't want to get out of bed) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced AGITATION (Agitated), HYPOTENSION (low blood pressure), ANXIETY (anxious and jittery) and FATIGUE (fatigued, didn't want to get out of bed). At the time of the report, AGITATION (Agitated), HYPOTENSION (low blood pressure), ANXIETY (anxious and jittery) and FATIGUE (fatigued, didn't want to get out of bed) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications details were not reported by the reporter. Treatment details was not reported by the reporter.
Sensation that my brain was on fire or oddly fevered even though my body's temperature did not elivate; severe joint pain; very thirsty; This is a spontaneous report from a contactable consumer (patient) via a Pfizer Sponsored Patient Program COVAES. A 59-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 24Mar2021 at 11:30 (Lot number: ER8730) on the left arm as single dose for COVID-19 immunization. Medical history included allergy to cats, asthma from allergy. Concomitant medications were not provided. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 01Mar2021 at 09:30 (Lot number: EN6205) on the left arm as single dose for COVID-19 immunization. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient did not diagnose with COVID-19 and since the vaccination, the patient had not been tested for COVID-19. Patient reported that sensation that his brain was on fire or oddle fevered even though his body's temperature did not elevate, not a headache on 24Mar2021 at 22:00. On 24Mar2021 at 22:00, patient also had severe joint pain and very thirsty; lasted about 36 hours. There was no treatment received for the adverse events. The outcome of events was recovered on unspecified date.  Information on the lot/batch number has been requested.
hives/ Wheals, urticaria, hives on back, neck, face/chronic urticaria; joint pain of hands, feet, knees, fingers/ arthritis/ swelling around the joints; shingles; sweaty; dizzy episodes; feeling sick; nausea; vomiting; headaches; This spontaneous report was received from a registered nurse who called on behalf of her 15 years old daughter. The patient's medical history included mild eczema. The patient had no known drug allergy and reported no concomitant medications.    On 29-DEC-2011, the patient was vaccinated with dose 1 quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine (GARDASIL) (lot #, dose and expiry not reported). There was no concomitant medication. On 28-JAN-2012, the patient broke out in shingles. On 29-FEB-2012, the patient was vaccinated with dose 2 of quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine (GARDASIL) (lot#, dose and expiry not reported). In the last week in March 2012 and beginning of April 2012, the patient developed hives. The nurse took her daughter for a doctor visit 06-JUN-2012 and she was told the hives was not due to the quadrivalent Human papillomavirus (Types 6,11,16,18) recombinant vaccine (GARDASIL). Patient received treatment with triamcinolone cream. The patient was then referred to an allergist. On 11-JUL-2012, patient was vaccinated with dose 3 of quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine (GARDASIL) (lot#, dose and expiry not reported). In approximately 01-AUG-2012 (reported as "about three weeks post vaccination"), the patient developed wheals, urticaria, and joint pain of hands, feet, knees, fingers. Hives on her back, neck, face. The patient was taken to the emergency room twice once in September 2012 and another visit in October 2012. Unspecified test for vasculitis were performed which were negative. The patient was treated with prednisone and diazepam (VALUM) and released. On an unknown date in 2012, the patient also experienced dizzy episodes, sweaty and feeling sick, had nausea, vomiting and headaches. The patient's present status was reported as not recovered.   Follow up information was received from a physician, via social media. The patient was 14 when she had the reaction to the quadrivalent Human papillomavirus (Types 6,11,16,18) recombinant vaccine (GARDASIL) vaccine. It was reported that the patient suffered from chronic urticaria and arthritis, a severe skin allergy, after quadrivalent Human papillomavirus (Types 6,11,16,18) recombinant vaccine (GARDASIL) vaccination. She had had daily hives and continued to suffer from arthritis. It was reported that chronic urticaria could have been caused by quadrivalent Human papillomavirus (Types 6,11,16,18) recombinant vaccine (GARDASIL).
I had tremors for 48 hours after the shot, starting about 2 hours after shot also had a choking feeling. I took Benadryl before and after.
Pt received HPV while sitting in a chair in exam room.  Nursing staff stepped out to get a supply for a blood draw and came back in to notice patient not looking well.  Patient stated she was seeing stars so nursing staff assisted her to exam table and had her lie down.  As patient was lying down her eyes rolled back and she had some twitching of her right arm. Pulse oximeter applied.  Read at 98%. O2 administered.
lump by chavicol/mass; he has a node on her thyroid; swelling on the neck; Itchiness in both arms; stinging pain; Lymph node; Headache; Soreness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Soreness), PRURITUS (Itchiness in both arms), AXILLARY PAIN (stinging pain), LYMPH NODE PAIN (Lymph node) and HEADACHE (Headache) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history). Concomitant products included METFORMIN, LEVOTHYROXINE SODIUM (LEVOTIROXIN), LOVASTATIN, ATENOLOL and LOSARTAN for an unknown indication.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1. On 04-Feb-2021, the patient experienced PAIN (Soreness) and HEADACHE (Headache). On 08-Feb-2021, the patient experienced PRURITUS (Itchiness in both arms), AXILLARY PAIN (stinging pain) and LYMPH NODE PAIN (Lymph node). At the time of the report, PAIN (Soreness), PRURITUS (Itchiness in both arms), AXILLARY PAIN (stinging pain), LYMPH NODE PAIN (Lymph node) and HEADACHE (Headache) outcome was unknown.            Treatment included Advil and concomitant medication.
Chills; Tired; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills) and FATIGUE (Tired) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypoglycemia (he has hypoglycemia for about 4 years).   On 06-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced CHILLS (Chills) and FATIGUE (Tired). At the time of the report, CHILLS (Chills) and FATIGUE (Tired) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood glucose: (Low) hypoglycemia.         No concomitant drug information was provided by reporter.No treatment information was provided.      This case was linked to MOD-2021-015896 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 24-Jun-2021: Follow-up information received on 24 Jun 2021 contains non- significant information On 14-Jul-2021: Added second dose information.
FEVER; This spontaneous report received from a consumer concerned a female of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow up to request batch/lot number. No concomitant medications were reported. On an unspecified date, the subject experienced fever. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 102 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of fever was not reported. This report was non-serious.
On 7/15/2022- I had awful cough, fatigue, and very grumpy. On 7/15/2022, I took a home test COVID-19 and it was positive. I called health line, they called in a prescription. They prescribed a medication that started with an "M". It was not Paxlovid.  I started feeling better after a couple of days after taking the prescription. I did not feel horrible. I just had a bad cough and fatigue.
Redness approx 4x4" (L) deltoid area, raised and felt warm. Headache got worse and visual disturbance increased. T-98, B/P - 144/88. Seen by Dr.
Muscle aches, headache,  anxiety, restless leg, sore armpit, sore arm , tiredness
MD (Physician) Hospitalist          Physician Discharge Summary     Patient ID:   72 y.o.       Admit Date:  9/2/2022     Discharge Date:   9/5/2022     Discharge Diagnosis:  Principal Problem:    NSTEMI (non-ST elevated myocardial infarction)  Active Problems:    PAF (paroxysmal atrial fibrillation)    COVID-19 virus detected    Dementia without behavioral disturbance    Essential hypertension        Hospital Course:  72 year old female with dementia was admitted for NSTEMI and testing (+) for Covid-19. Cardiology saw her and stress test showed low risk and TTE showed normal LVEF. She has been ambulating and not hypoxic. She will be discharged home today in stable condition. Follow up with Primary Care Doctor in 5-7 days.     Physical Exam on the day of discharge:  Last Recorded Vital Signs: Temp: 98 °F (36.7 °C)  Heart Rate (Monitor): 71  Pulse: 72  BP: 125/67  Respirations: 18  SpO2: 94 %  O2 Flow Rate (l/min): 0 l/min  General Appearance: no distress   Eyes: PERRLA  ENT: moist mucus membranes, no adenopathy  Lungs: clear to auscultation bilaterally   Heart: irregular rate and rhythm  Abdomen: soft, non-tender   Skin: No rashes or lesions   Extremities: full ROM  Neuro: disoriented     Consults:  IP CONSULT TO CARDIOLOGY  IP CONSULT TO CARDIOLOGY  IP CONSULT TO SOCIAL WORK     Significant Diagnostic Studies:   Stress test, TTE     Operations: none     Disposition:  Home      Discharge Condition:  Fair
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 65-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 28Sep2022 at 17:00 as dose 5 (booster), single (Lot number: GH6739) at the age of 64 years, in left arm for covid-19 immunisation; bnt162b2 (BNT162B2), on 04Jun2022 at 10:00 as dose 4 (booster), single (Lot number: FM7553), in left arm for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Underactive thyroid" (unspecified if ongoing); "Osteporosis" (unspecified if ongoing); "light plague carotid artery" (unspecified if ongoing); "Known allergies: Acromycin" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Erythromycin, reaction(s): "Known allergies: Erythromycin". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 03Oct2023, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (03Oct2023) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19.
3/2 MHC, admitted day after covid vaccine with arterial clot. Patient seen for left lower extremity arterial occlusion with critical limb ischemia. The patient was transferred immediately post-operatively to the Progressive Care Unit for observation. The next morning the patient was discharged home with stable vital signs, clean, dry, and intact wounds, good pain control, and vascular exam of +BLE PT and DP doppler signals.
This spontaneous report was received from a medical assistant and refers to a multiple unspecified patients of unknown age and gender. On unknown dates, the patients were vaccinated with an improperly stored dose of VAQTA lot # M038572 with expiration date of 11-MAR-2018 or lot #M047658 with expiration date of 28-OCT-2017. No adverse effects were reported. The digital data logger was involved in recording the excursion. The vaccines were exposed to temperature excursion between 32 Fahrenheit degrees and 35 Fahrenheit degrees for 30 minutes. This is one of six reports received from the same reporter.; Sender's Comments: US-009507513-1708USA005170:  US-009507513-1708USA005168: US-009507513-1708USA005169: US-009507513-1708USA005166: US-009507513-1708USA001493:
This spontaneous report was received from a pharmacist regarding a 60 years old male patient. The patient had no pertinent medical history, concurrent conditions and drug allergies. On 12-JUL-2016, the patient was vaccinated with ZOSTAVAX 19400 PFU injection, 0.65 ml, subcutaneously, lot # L046893, expiration date 28-FEB-2017. The patient had no concomitant therapies. In approximately July 2016 (reported as "within 1 week of receiving vaccine"), the patient developed an "active case of shingles" (herpes zoster) and sought medical attention. The patient was prescribed a treatment of "VALTREX 1 gram three times per day for 1 week and an unspecified dosage of Gabapentin". No laboratory diagnostics were performed and no product quality complaint was involved. The outcome of herpes zoster and the causal relationship between herpes zoster and ZOSTAVAX were unknown. Additional information has been requested.
A report has been received from a literature source via regulatory authority, vaccine adverse event reporting system (VAERS) concerning a female patient. The patient's medical history, concomitant diseases and concomitant medications were not reported. On an unknown date, the patient received FLUMIST (Intranasal) while the patient was pregnant. It was reported that the patient had sinusitis. The outcome of the events was unknown. Also the outcome of pregnancy was unknown. The report was considered to be non-serious. Based on the information in this report, and awaiting the reporter's assessment, the company physician considered the event of sinusitis to be not related to the suspect drug FLUMIST. The company causality was implied to be no for the event of pregnant patient received LAIV3.
pt recv vax 13FEB97 930AM & 5PM devel t104 & had APAP q 4hr since vax;taken to hosp that PM & told to cont w/APAP;was vague about the cause of fever but looked in ears & throat & were nl;temp nl around MN;next AM fine;
Patient was given a Flu shot on 08/22/2017, called a day later stating her arm was hurting. She was advised that this is a normal occurrence and it should take a few days for the soreness to go away. She had a doctor's appointment with her Doctor a few months later around October 2017, and brought up the problem of her arm hurting but the doctor also told her to give it some more time for it to go away. Patient then visited pharmacy on 01/27/2018 around 4pm stating that it was still hurting and what to go from there. Pharmacist who administered the vaccination notified the doctor (faxed and left voicemails) to let them know and what the next course of action can be to help the patient on 01/29/2018.
I felt as if my veins were throbbing extremely hard. It caused me to be in alot of pain. I also got red bumps all over my right breast. The bumps went away within 2 weeks and the throbbing is a current issue.
Red rash developed around the injection site: about 6 inches in diameter. No other complaints.
Fatigue, mentally "fuzzy", muscle tightness/aches in shoulders and upper back
This case was reported by a pharmacist via call center representative and described the occurrence of injection site swelling in a 71-year-old female patient who received SHINGRIX for prophylaxis. On 18th September 2018, the patient received the 2nd dose of SHINGRIX. On 19th September 2018, 1 days after receiving SHINGRIX, the patient experienced injection site swelling, injection site pain and red blotches. On an unknown date, the outcome of the injection site swelling and red blotches were unchanged and the outcome of the injection site pain was recovering/resolving. It was unknown if the reporter considered the injection site swelling, injection site pain and red blotches to be related to SHINGRIX. Additional details were reported as follows: The pharmacist reported that the patient received a dose of SHINGRIX vaccine at a pharmacy in left arm. The reporter put the patient on the phone, the patient stated that she experiencing swelling and pain at the injection site, along with red blotches covering area of 2 by 3 inches right below the injection site. On 19th September 2018, the patient noticed all of the symptoms. The pain at the injection site was better than the day before reporting. Swelling and red blotches are still unchanged.
Day 7 thru 9 post injection site had redness, swelling, and tenderness lasting total of 72 hours maximum.
Patient complained of sore and painful arm the day after injection, but injection became red and inflammed 2 days later.
CELLULITIS OF LEFT UPPER THIGH 2.5CM TREATED WITH SCRIPT FOR CEPHALEXIN 250MG/5ML ORAL SUSPENSION
(after booster dose)loss of appetite; (after booster dose)she felt very weak.; (after booster dose)mostly fatigue; (after booster dose)chills; (after booster dose)headache; (after booster dose)fever; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED APPETITE ((after booster dose)loss of appetite), ASTHENIA ((after booster dose)she felt very weak.), FATIGUE ((after booster dose)mostly fatigue), CHILLS ((after booster dose)chills) and HEADACHE ((after booster dose)headache) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 04-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DECREASED APPETITE ((after booster dose)loss of appetite), ASTHENIA ((after booster dose)she felt very weak.), FATIGUE ((after booster dose)mostly fatigue), CHILLS ((after booster dose)chills), HEADACHE ((after booster dose)headache) and PYREXIA ((after booster dose)fever). At the time of the report, DECREASED APPETITE ((after booster dose)loss of appetite), ASTHENIA ((after booster dose)she felt very weak.), FATIGUE ((after booster dose)mostly fatigue), CHILLS ((after booster dose)chills), HEADACHE ((after booster dose)headache) and PYREXIA ((after booster dose)fever) outcome was unknown.            Patient was born in 1951.  Concomitant medication was not reported.   Symptoms started on ??-NOV-2021.   Treatment medication information was not provided.   This case was linked to MOD-2021-378184 (Patient Link).
Expired vaccine used; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 04-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 04-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.       For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication listed.   No treatment information provided.
Flu-like symptoms.  Severe body aches, chills, exhaustion, coughing, tight chest, headache, nausea
PATIENT COMPLAINED HER ARM WAS HOT TO THE TOUCH AND HAD REDNESS.
Measured 3 1/2 cm x 4 cm on 2-25-11, area red & hard. Physician prescribed steroid & Ibuprofen 3-4 tabs 2x per day. Hot/cold compress 3x/d for 10 min.
Pfizer vaccine!! I have severe heart CNS organ failures and this vaccine is the cause!! Heart, brain, lungs, skin, I'm dying and Drs don't believe the trympansoma and all the metals in vaccines!! I'm dying!!
This spontaneous report was received from a physician, via field representative, refers to a female patient of unknown age. On an unknown date the patient was vaccinated with GARDASIL dose 1, 0.5 ml, intramuscular. In approximately June 2013 reported as: (within past month) the patient fainted after administration her first dose of GARDASIL, had fallen and cut her eye. The outcome of both events was reported as recovering/resolving. The relatedness was not reported. Patient did not seek medical attention. Case is linked same reporter MARRS case # 1307USA015183, where 5 other patients fainting on GARDASIL are described. Additional information has been requested.